Welcome to our dedicated page for Chromadex news (Ticker: CDXC), a resource for investors and traders seeking the latest updates and insights on Chromadex stock.
About Chromadex Corp
Chromadex Corp (CDXC) is a globally recognized integrated nutraceutical and bioscience company committed to improving the quality of life through advanced research on healthy aging. The company is deeply invested in understanding the mechanisms by which cellular processes, particularly those involving nicotinamide adenine dinucleotide (NAD+), impact the aging process. With a core focus on innovative science, Chromadex has developed a multifaceted business model that spans from research breakthroughs to commercially available consumer products, ensuring that its scientific discoveries translate into meaningful daily benefits.
Business Model and Core Segments
Chromadex’s operational framework is built on three primary segments that work in unison to deliver high-quality, science-based nutraceutical innovations:
- Consumer Products: This segment is primarily responsible for marketing and distributing products directly to the consumer market. Its portfolio features formulations designed to support healthy aging by leveraging proprietary, scientifically validated ingredients. The company’s flagship product, built around the NAD+ precursor nicotinamide riboside (NR), exemplifies its commitment to translating rigorous research into everyday solutions.
- Ingredients Segment: Focused on the development and licensing of novel ingredients, this segment utilizes high-caliber scientific research to create bioactive compounds. These innovations are targeted for use in various applications, ranging from dietary supplements to functional foods, ensuring that the expertise of Chromadex is shared widely across the industry.
- Analytical Reference Standards and Services: This area underpins the rigorous quality control and analytical validation processes that are crucial to research and product development. By offering specialized standards and services, Chromadex supports both internal development and external quality assurance needs in a scientifically robust manner.
Research and Innovation
At the heart of Chromadex’s operations is a steadfast commitment to research and development. The company partners with leading universities and research institutions worldwide to explore the potential of critical biochemical pathways related to aging. This collaborative approach not only strengthens its research capabilities but also ensures that the ingredients developed are based on solid scientific evidence. The integration of cutting-edge bioscience and precise analytical methodologies solidifies its position as a trusted name in the nutraceutical industry.
Market Position and Competitive Differentiation
Chromadex distinguishes itself by focusing on the intersection of scientific innovation and consumer wellness. Its emphasis on NAD+ research, an area that has increasingly become synonymous with the study of aging and cellular health, sets it apart in a competitive landscape that includes various bioscience and nutraceutical companies. The company’s multidimensional approach, which bridges direct consumer engagement with deep scientific inquiry, provides a unique value proposition that caters both to health-conscious individuals and to industry partners seeking high-quality, science-backed ingredients.
Commitment to Transparency and Quality
Transparency in research and product development is a core tenet of Chromadex’s philosophy. Every stage of its process—from initial scientific exploration to the final formulation—undergoes rigorous analytical review and quality control. This disciplined approach reassures consumers and industry collaborators alike, fostering trust and establishing Chromadex as a reliable source of scientifically supported nutraceutical innovations.
Integrating Science and Consumer Wellness
The company’s approach is marked by a detailed understanding of biochemical processes and a commitment to translating this expertise into practical health solutions. With its diversified business segments, Chromadex not only addresses the needs of a broad consumer base but also solidifies its reputation among researchers and industry experts. Its dedicated exploration of key ingredients such as nicotinamide riboside, alongside other innovative compounds, continues to influence the realm of healthy aging and functional nutrition.
ChromaDex Corp. (NASDAQ:CDXC) has announced it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after market close. The company will host an investor conference call to discuss the results and provide a business update on Wednesday, November 6, 2024, at 4:30 p.m. ET. Management encourages participants to join 10 minutes before the call. A replay will be available from 7:30 p.m. EDT on November 6 until 11:59 p.m. EDT on November 13, 2024.
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, has announced its participation in the 17th Annual LD Micro Main Event at the Luxe Sunset Boulevard Hotel, California on October 29th, 2024. CEO Rob Fried and CFO Ozan Pamir will deliver a presentation at 2:00pm PT (5:00pm ET). The event will showcase 150 companies and include private one-on-one meetings with institutional investors. ChromaDex management will be available for individual meetings throughout the day. Interested parties can watch the live presentation through a provided webcast link and access additional company information through the LD Micro profile page.
ChromaDex Corp. (NASDAQ:CDXC) announced that Dr. Yasmeen Nkrumah-Elie, their Global Director of External Research, has been honored with the inaugural Trailblazing Woman Award by Radicle Science and the Council for Responsible Nutrition (CRN). This award recognizes Dr. Nkrumah-Elie's contributions to the dietary supplement and functional food industry through leadership, innovation, and mentorship.
Dr. Nkrumah-Elie has led ChromaDex's External Research Program (CERP) to become an industry-leading initiative with nearly 300 research collaborations worldwide, over 30 published clinical trials, and several intellectual property opportunities. She is also active in various industry organizations, advocating for diversity, equity, and inclusion.
The award highlights Dr. Nkrumah-Elie's commitment to advancing scientific excellence, promoting diversity, and mentoring the next generation of female leaders in the industry.
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ and healthy-aging research, has announced its participation in the Lytham Partners Fall 2024 Investor Conference. CEO Rob Fried will engage in a fireside chat on October 1, 2024, at 1:15 PM ET, moderated by Sean McGowan from Roth Capital Partners. The webcast will be accessible via a provided link and the company's website.
Additionally, Fried and Wesley Yu, VP of Finance, will host virtual one-on-one meetings with investors. Interested parties can arrange meetings through Lytham Partners or register for the event online. This participation underscores ChromaDex's commitment to investor relations and showcases its position in the healthy-aging research sector.
ChromaDex Corp. (NASDAQ:CDXC) has appointed Ozan Pamir as Chief Financial Officer, effective October 21, 2024. Mr. Pamir will oversee all corporate finance matters, including accounting, strategic financial planning, and investor relations, reporting directly to CEO Rob Fried. Prior to joining ChromaDex, Pamir served as CFO of 180 Life Sciences, where he played a key role in the company's NASDAQ listing and managed funding rounds. He has also worked with two early-stage biotech companies as CFO and board member, and was previously VP of Investment Banking at a leading independent investment bank. Mr. Pamir holds an Economics and Finance degree from McGill University and is a CFA Charterholder.
ChromaDex Corp. (NASDAQ:CDXC) has announced the expansion of its pharmaceutical-grade Niagen® (nicotinamide riboside chloride) IV and injection offerings to 14 additional leading wellness clinics across the United States. This follows the successful debut of quantities in select clinics last month. Wells Pharma of Houston, a U.S. FDA-registered 503B outsourcing facility, will compound and distribute the product, branded as Niagen+, exclusively to these clinics with a prescription.
Niagen, ChromaDex's flagship ingredient, is clinically proven to elevate NAD+ levels, important for cellular health. The IV and injection formulations offer rapid and efficient delivery, outperforming NAD+ IV in a pilot clinical study with superior tolerability, 75% shorter infusion time, and a significant 20% increase in whole blood NAD+ levels. Several clinic directors have expressed excitement about the potential of Niagen IV in health optimization and longevity treatments.
ChromaDex Corp. (NASDAQ:CDXC) celebrates its 25th anniversary as a pioneer in NAD+ research and healthy aging solutions. Founded in 1999, ChromaDex has evolved from an analytical testing company to a leader in developing proprietary ingredients for dietary supplements. The company's flagship product, Tru Niagen®, is the top NAD+ supplement for healthy aging in the U.S., with over 8 million bottles sold.
Key achievements include:
- Licensing patents for Dr. Charles Brenner's nicotinamide riboside (NR) research in 2012
- Launching Niagen®, the first patented form of NR, in 2013
- Introducing pharmaceutical-grade Niagen+™ for intravenous therapy in 2024
- Establishing the ChromaDex External Research Program (CERP™), which has facilitated over 275 research agreements globally
- Building a portfolio of 90+ patents related to NAD+ precursors
To mark this milestone, ChromaDex is offering a 25% discount on lifelong Tru Niagen® subscriptions and one-time purchases until September 12, 2024.
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, will participate in Renmark's Virtual Non-Deal Roadshow Series on Thursday, August 29, 2024, at 2:00 PM EDT. The event will feature a presentation by key executives, including CEO Rob Fried, Interim CFO James Lee, and VP Finance Wesley Yu.
The live presentation will cover ChromaDex's latest investor information, followed by a Q&A session. While live event registration may be , a replay will be available on the company's investor website. Interested parties can register for the event using the provided link, and are advised to use the latest version of Google Chrome for optimal connectivity.
This virtual roadshow offers an opportunity for stakeholders, investors, and followers to gain insights into ChromaDex's current initiatives and future prospects in the field of healthy aging and NAD+ research.
ChromaDex Corp. (NASDAQ:CDXC) has secured U.S. Patent number 10,000,520 C1 for the composition of matter of salt forms of NMNH (dihydronicotinamide mononucleotide), a precursor to NAD+. This patent, co-owned with Queen's University Belfast, grants ChromaDex exclusive rights to the disodium salt form of NMNH. The company now has over 80 patents related to NAD+ precursors, including its flagship ingredient Niagen® (nicotinamide riboside).
NMNH is distinct from NMN, which was banned as a dietary supplement by the FDA in 2022. While NMNH has shown promise in preclinical studies, further research is needed to determine its oral bioavailability and safety as a dietary supplement. Currently, NMNH's legal status as a dietary supplement is questionable due to lack of proper FDA notification as a new dietary ingredient (NDI).
ChromaDex Corp. (NASDAQ:CDXC) reported strong Q2 2024 financial results, with total net sales of $22.7 million, up 12% year-over-year. Tru Niagen® sales reached $18.6 million, a 10% increase. The company achieved a gross margin of 60.2% and reduced operating expenses by $0.7 million compared to the prior year quarter. ChromaDex reported an approximately breakeven net loss and positive Adjusted EBITDA of $1.6 million.
Key developments include receiving U.S. FDA Orphan Drug Designation for nicotinamide riboside chloride to treat Ataxia Telangiectasia, and launching Niagen+, a pharmaceutical-grade product line. The company also introduced Niagen+ NAD+ Test Kits for healthcare practitioners. For the full year 2024, ChromaDex expects 10-15% revenue growth and slightly improved gross margins.